Cystic Fibrosis Drug Ivacaftor Eases Lung Scarring in Mice by Rejuvenating Aging Air Sac Cells

Ivacaftor, the cystic fibrosis drug also known as VX-770, has emerged as a candidate treatment for idiopathic pulmonary fibrosis in a new study published in Cell Death Discovery. Researchers led by first author Shuang Wu and senior author Xiaoming Liu report that pharmacologic potentiation of the CFTR protein reduced experimental pulmonary fibrosis in mice by targeting senescence in alveolar type 2 cells, the cells that maintain the lung’s gas-exchange surface. The work provides preclinical evidence that acquired CFTR dysfunction may be a druggable driver of fibrosis.

The starting point was a clinical observation: lungs from patients with idiopathic pulmonary fibrosis show reduced expression of CFTR, the cystic fibrosis transmembrane conductance regulator, with the loss most pronounced in alveolar type 2 cells, which normally carry high levels of the channel. Whether that acquired dysfunction contributes to disease development has remained unclear. To test the idea, the investigators used a bleomycin-induced pulmonary fibrosis mouse model and treated the animals with VX-770, a small-molecule potentiator that boosts CFTR channel activity.

VX-770 treatment reduced pulmonary fibrosis by limiting collagen deposition and restoring normal lung structure and function. The drug also reestablished epithelial homeostasis: aberrant KRT8-positive transitional cells decreased, and the treatment prevented the loss of alveolar type 1 cells, the thin cells that form most of the alveolar surface. Potentiating CFTR thus appeared to steer injured epithelium back toward its normal differentiated state rather than the scar-promoting trajectory of fibrosis.

The findings on aging biology are central. VX-770 diminished cellular senescence both in vivo and in AT2 cell organoid cultures, decreasing the expression of senescence markers and the pro-fibrotic senescence-associated secretory phenotype, the inflammatory cocktail that senescent cells release. Senescence of alveolar type 2 cells is considered a major factor driving idiopathic pulmonary fibrosis, disrupting epithelial homeostasis and promoting fibrotic remodeling, so a licensed drug that suppresses these programs in the affected cells has obvious translational appeal.

To confirm the effect ran through CFTR rather than an off-target action, the researchers deleted CFTR specifically in alveolar type 2 cells. That maneuver lessened the therapeutic effect of VX-770, confirming its target-specific action.

Mechanistically, the study links a chloride channel to a tumor suppressor. VX-770 stabilized the CFTR-PTEN protein complex, elevating PTEN levels and thereby inhibiting the pro-fibrotic PI3K/AKT signaling pathway. The authors frame this as evidence that acquired CFTR dysfunction is a key druggable driver of pulmonary fibrosis, with channel potentiation acting as a senescence-targeting intervention.

The implications extend beyond lung biology. Ivacaftor is already approved for cystic fibrosis, so its safety profile and dosing in humans are largely known, and repurposing it could in principle move faster than a de novo program. The authors position their findings as preclinical evidence supporting the repurposing of VX-770 as a novel senescence-targeting therapy for idiopathic pulmonary fibrosis, a deadly disease that urgently requires effective treatments.

Caution is warranted, as with any mouse model. Bleomycin-induced fibrosis captures only part of the human disease, which arises over decades in older adults. Whether CFTR potentiation can reverse established fibrosis in humans, whether the organoid findings translate to patient lungs, and what dose would be needed all remain open questions. The study also does not establish that CFTR dysfunction causes idiopathic pulmonary fibrosis on its own; it shows that restoring channel function modifies experimental disease.

Subject of Research: Preclinical testing of the CFTR potentiator ivacaftor as a senescence-targeting therapy for pulmonary fibrosis

Article Title: Pharmacologic CFTR potentiation attenuates alveolar epithelial senescence and experimental pulmonary fibrosis

Article References: Wu, S., Yang, L., Ma, Y., Hu, Z., Jinag, L., Tata, A., Xue, J., Wang, J., Campbell, K. D., Wang, C., Chen, J., Wang, Y., Engelhardt, J. F., & Liu, X. (2026). Pharmacologic CFTR potentiation attenuates alveolar epithelial senescence and experimental pulmonary fibrosis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03372-9

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03372-9

Keywords: idiopathic pulmonary fibrosis, CFTR, ivacaftor, VX-770, alveolar type 2 cells, cellular senescence, PTEN, PI3K/AKT signaling, bleomycin model, drug repurposing, organoids, lung fibrosis